Nove farmakološke strategije u lečenju nemikrocelularnog karcinoma pluća

  • Irena Kostić Institut za patološku fiziologiju Medicinski fakultet Kragujevac

Sažetak


Prema broju umrlih karcinom pluća je vodeći ubica u odnosu na sve ostale karcinome, a nemikrocelularni karcinom pluća (NSCLC) je njegov najčešći podtip. Zbog velike učestalosti oboljevanja od nemikrocelularnog karcinoma pluća cilj rada je da prikaže nove farmakološke mogućnosti u terapiji ovog agresivnog karcinoma. Postoje dva pravca istraživanja novih lekova, drugačijih po mehanizmu delovanja od standardne hemioterapije. Jedan pravac vodi ka specifičnoj ciljnoj terapiji usmerenoj protiv određenih molekula na kancerskim ćelijama, poput blokatora faktora rasta, ili inhibitora prenosa signala u ćeliju (kao što su inhibitori tirozin kinaza, odnosno serin-treonin kinaza), dok je drugi put okrenut ka pronalaženju lekova koji bi mogli da podstaknu imunski sistem na uništenje tumora (poput inhibitora receptora za programiranu smrt, njegovih liganada, ili antagonista MAGE-A3). Neki od ovih lekova su odobreni od strane Američke agencije za hranu i lekove, dok su drugi u početnim fazama kliničkog ispitivanja lekova.

Reference

Brandao GDA, Brega EF, Spatz A. The role of molecular pathology in non-small-cell lung carcinoma-now and in the future. Curr Oncol 2012;19(1):S24-S32

Travis WD, Brambilla E, Van Schil P, et al. Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification. Eur Respir J 2011;38:239-243

Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191

Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551

Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232

Bell DW, Brannigan BW, Matsuo K, et al. Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms. Clin Cancer Res 2008;14:4079-4084

Reungwetwattana T, Weroha SJ, Molina JR. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer 2012;13(4):252-266

Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-2246

Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small-cell lung cancer: subset analyis from the ISEL study. J Thorac Oncol 2006;1:847-855

Mok T, Wu YL, Thongprasert S, et al. Phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer. Ann Oncol 2008;19(Suppl 8) (viii 1,Abstract LBA2)

Jiang H. Overview of gefitinib in non-small cell lung cancer: An Asian perspective. Jpn J Clin Oncol 2009;39(3):137-150

Armour A. Gefitinib in advanced non-small cell lung cancer: Clinical experience in patients of Asian origin. Asia Pac J Clin Oncol 2007;3:66-78

Tamura K, Okamoto I, Kashii T, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 2008;98:907-914

Sequist LV, Martins R, Spigel DR, et al. First-line gefitinib in patients with advanced non-small cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-2449

Liu W, Innocenti F, Chen P, Das S, Cook EH Jr, Ratain MJ. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 2003;9:1009-1012

Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388

Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:2121-2127

Tarceva (erlotinib), Highlights on prescribing information. OSI Pharmaceuticals/Genentech, 2012. Available at: http://www.gene.com/gene/products/information/pdf/tarceva-prescribing.pdf (Accessed on August 24, 2012)

Cappuzzo F, Ciuleanu T, Stelmakh L, et al. SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 2009;27:8001

Garassino MC, Martelli O, Bettini A, et al. TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR. J Clin Oncol 2012(suppl): abstr.LBA7501

Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PloS Med 2005;2(3):e73

Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ErbB3 signaling. Science 2007;316:1039-1043

Zucali PA, Ruiz MG, Giovannetti E, et al. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 2008;19:1605-1612

Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-925

Ludovini V, Bianconi F, Pistola L, et al. Optimization of patient selection for EGFR-TKIS in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Cancer Chemother Pharmacol 2012;69(5):1289-1299

Yang JC-H, Schuler MH, Yamamoto N, et al. LUX-lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 2012;30(suppl); abstr LBA7500

Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012;13(5):528-538

Van Erp N, Gerdelblom H, Guchelaar H. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009;35(8):692-706

Rukazenkov Y, Speake G, Marshall G, et al. Epidermal growth factor receptor tyrosine kinase inhibitors: Similar but different? Anticancer Drugs 2009;20(10):856-866

Burtness B, Anadkat M, Basti S, et al. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Cancer Network 2009;7(Suppl 1):S5-S21

Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566

Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the Western population. Clin Cancer Res 2009;15:5216-5223

Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an Alk kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-4283

United States, Department of Health and Human Services, Food and Drug Administration (FDA). Crizotinib (Web page). Silver Spring, MD: FDA; 2011. (Available at: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm270058.htm ; Accesses on August 29, 2012)

Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703

Shaw AT, Camidge DR, Engelman JA, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol 30, 2012 (suppl); abstr 7508

Kranenburg O. The KRAS oncogene: past, present, and future. Biochim Biophys Acta 2005;1756:81-82

Loriot Y, Mordant P, Deutsch E, Olaussen KA, Soria JC. Are ras mutations predictive markers of resistance to standard chemotherapy? Nat rev Clin Oncol 2009;6:528-534

Capella G, Cronauer-Mitra S, Pienado MA, Perucho M. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environ Health Perspect 1991;93:125-131

Roberts PJ, Der CJ. Targeting the Raf-Mek-Erk mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-3310

Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-1765

Zhu C-Q, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26(26):4268-4275

Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of K-ras mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008;14:5731-5734

Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634

Gautschi O, Huegli B, Ziegler A, et al. Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett 2007;254:265-273

Mascaux C, Iannino N, Martin B, et al. The role of ras oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005;92:131-139

Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012;104:228-239

Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010;28:744-752

Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the Raf-Erk signaling pathway by oncogenic mutations of B-raf. Cell 2004;116:855-867

Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954

Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011;29:3574-3579

Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011;29:2046-2051

Falchook GS, Long GV, Kuryrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012;379(9829):1893-1901

Holt SV, Logie A, Davies BR, et al. Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). Cancer Res 2012;72(7):1804-13

Meng J, Dai B, Fang B, et al. Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo. PLoS ONE 2010;5(11): e14124. doi:10.1371/journal.pone.0014124

Trejo CL, Juan J, Vicent S, Sweet-Cordero A, McMahon M. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E. Cancer Res 2012;72(12):3048-3059

Sang M, Lian Y, Zhou X, Shan B. MAGE-A family: attractive targets for cancer immunotherapy. Vaccine 2011;29:8496-8500

Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443-54

Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366(26):2455-65

Objavljeno
2014/06/28
Rubrika
Pregled literature